Adamis Pharmaceuticals Announces FDA Acceptance for Review for the Supplemental New Drug Application

Adamis Pharmaceuticals (NASDAQ:ADMP) announced that the U.S. Food and Drug Administration (“FDA”) has accepted for review the Company’s supplemental New Drug Application (“sNDA”) for its low dose SymjepiTM  product candidate for the emergency treatment of anaphylaxis.

As quoted in the press release:

The FDA further indicated that no potential review issues were identified and if no major deficiencies were identified in their continued review, they are targeting September 3, 2018 to communicate proposed labeling and, if necessary, any postmarketing requirement/commitment requests.

Click here to read the full press release.

Are You Aware of the FDA's Plans for 2018?

Find out what's going on in our new report
 

Get the Latest Pharmaceutical Investing Stock Information

Get the latest information about companies associated with Pharmaceutical Investing delivered directly to your inbox.

Pharmaceutical

By selecting company or companies above, you are giving consent to receive email from those companies. And remember you can unsubscribe at any time.

Are You Aware of the FDA's Plans for 2018?

Find out what's going on in our new report
 
Comments

Leave a Reply